Radioimmunoassays in Analytical Methods in Human Toxicology

  • G. W. Aherne


As man has used more and more chemical substances in his daily life, the subject of human toxicology has necessarily become increasingly important. One of the highest causes of human toxicity from chemical substances is the use of drugs whether for therapeutic or other purposes. Since the introduction of more stringent regulations for the registration of drugs it has become necessary to study the pharmacokinetics and pharmacology of new (and old) drugs in great detail. There is also a greater awareness of the possible toxic effects of the many substances in every day use — both domestic and industrial. Concern about our environment is widespread.


International Atomic Energy Agency Immunisation Schedule High Avidity Human Toxicology Homogeneous Assay 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aherne, G. W. (1983). The specificity of morphine radioimmunoassays. Internal Congress and Symposium Series of The Royal Society of Medicine. No. 58, 21–9.Google Scholar
  2. Aherne, G. W. (1984). Use and significance of immunoassay in the analysis of water. Analyt. Proc. 21, 177–9.Google Scholar
  3. Aherne, G. W., Lawson, G. J., Quinton, M., and Marks, V. (1984). Drug determination in therapeutic and forensic contexts. In Reid, E. and Wilson, I. D. (eds.), Methodological Surveys in Biochemistry and Analysis Vol. 14, Plenum, London, 249–50.Google Scholar
  4. Aherne, G. W., English, J., and Marks, V. (1984). The role of immunoassay in the analysis of micro-contaminants in water samples. Ecotox env. Safety 9, 79–83.CrossRefGoogle Scholar
  5. Aherne, G. W. (1982). The specificity of morphine radioimmunoassays. Intl. Cong. Symp. Ser. Roy. Soc. Med. 58, 21–9.Google Scholar
  6. Aherne, G. W., and Marks, V. (1982). A radioimmunoassay for VP-16–213 in plasma. Cancer Chemother. Pharmacol. 7, 117–21.PubMedGoogle Scholar
  7. Aherne, G. W., James, S. L., and Marks, V. (1981). The radioiodination of bleomycin using iodogen. Clin. Chim. Acta 119, 341–3.CrossRefGoogle Scholar
  8. Aherne, G. W., Piall, E. M., and Marks, V. (1976). The radioimmunoassay of tricyclic antidepressants. Br. J. Clin. Pharmacol. 3, 561–5.PubMedCentralCrossRefPubMedGoogle Scholar
  9. Albano, J., and Ekins, R. P. (1970). In Proceedings of the Symposium on in vitro Procedures with Radioisotopes in Clinical Medicine and Research. International Atomic Energy Agency, Vienna, 491–512.Google Scholar
  10. Bolton, A. E., and Hunter, W. H. (1973). The labelling of proteins to high specific radioactivities by conjugation to a 125I-containing acylating agent. Biochem. J. 133, 529–39.PubMedCentralCrossRefPubMedGoogle Scholar
  11. Burke, C. W., and Shakespear, R. A. (1975). Rapid purification of triiodothyronine and thyroxine protein conjugates for antibody production. J. Endocr. 65, 133–8.CrossRefPubMedGoogle Scholar
  12. Butler, V. P., and Beiser, S. H. (1973). Antibodies to small molecules: biological and clinical applications. Adv. Immunol. 17, 255–310.CrossRefPubMedGoogle Scholar
  13. Collins, W. P., Barnard, G. J., Kim, J. B., Weerasekera, D. A., Kohen, F., Eshhar, Z., and Lindner, H. R. (1983). In Hunter, W. M. and Corrie, J. G. T. (eds.), Immunoassays for Clinical Chemistry, Churchill Livingstone, Edinburgh, 373–97.Google Scholar
  14. Ekins, R. P. (1974). Basic principles and theory. Br. Med. Bull. 30, 3–11.PubMedGoogle Scholar
  15. Ekins, R. (1981). In Voller, A., Bartlett, A., and Bidwell, D. (eds.), Immunoassays for the 80s, MTP Press, Lancaster, 5–17.CrossRefGoogle Scholar
  16. Ferrura, B., Milano, G., Ly, B., Guennec, J. Y., and Masseyeff, R. (1983). An enzyme immunoassay design using labelled antibodies for the determination of haptens: Application to methotrexate assay. J. Immunol. Methods 60, 257–69.CrossRefGoogle Scholar
  17. Findlay, J. W. A., Butz, R. F., and Jones, E. C. (1981). Relationships between immunogen structure and antisera specificity in the narcotic alkaloid series. Clin. Chem. 27, 1524–35.PubMedGoogle Scholar
  18. Fraker, P. J., and Speck, J. C. (1978). Protein and cell membrane iodinations with a sparingly soluble chloroamide 1,3,4,6-tetrachloro-3α, 6α, diphenylglycouril. Biochem. Biophys. Res. Commun. 80, 849–57.CrossRefPubMedGoogle Scholar
  19. Grabinski, P. Y., Kaiko, R. F., Walsh, T. D., Foley, K. M., and Houde, R. W. (1983). Morphine radioimmunoassay specificity before and after extraction of plasma and cerebrospinal fluid. J. Pharm. Sci. 72, 27–30.CrossRefPubMedGoogle Scholar
  20. Greenwood, F C., Hunter, W. H., and Glover, J. S. (1963). The preparation of131I-labelled human growth hormone of high specific radioactivity. Biochem. J. 89, 114–23.PubMedCentralCrossRefPubMedGoogle Scholar
  21. Harvey, M. H. (1983). The development and evaluation of a radioimmunoassay for the alkaloid solanidine in serum and the investigation of its levels in human serum. MSc Thesis, University of Surrey.Google Scholar
  22. Hunter, W. H., and Greenwood, F. C. (1962). Preparation of iodine-131 labelled human growth hormone of high specific activity. Nature 194, 495–6.CrossRefPubMedGoogle Scholar
  23. Hurn, B. A. L. (1974). Practical problems in raising antisera. Br. Med. Bull. 30, 26–8.Google Scholar
  24. Kamel, R. S., and Gardner, J. (1978). Preparation of125iodine-labelled methotrexate and its use in a magnetisable particle solid-phase radioimmunoassay. Clin. Chim. Acta 89, 363–70.CrossRefPubMedGoogle Scholar
  25. Landon, J., and Moffat, A. C. (1976). The radioimmunoassay of drugs. Analyst 101, 225–43.CrossRefPubMedGoogle Scholar
  26. Landsteiner, K. (1945). The Specificity of Serological Reactions, Harvard University Press, Boston. Reprinted by Dover, New York, 1962.Google Scholar
  27. Levitt, Y. (1977). Radioimmunoassay for paraquat. Lancet II, 358.CrossRefGoogle Scholar
  28. Lindstrom, L., Meurling, L., and Lovgren, T. (1982). The measurement of serum cortisol by a solid-phase chemiluminescence immunoassay. J. Steroid. Biochem. 16, 577–80.CrossRefPubMedGoogle Scholar
  29. Lucek, R., and Dixon, R. (1977). Specific radioimmunoassay for amitriptyline and nortriptyline in plasma. Res. Commun. Chem. Pathol. Pharmacol. 18, 125–35.PubMedGoogle Scholar
  30. Marks, V., Morris, B. A., and Teale, J. D. (1974). Pharmacology. Br. Med. Bull. 30, 80–6.PubMedGoogle Scholar
  31. Mason, P. A., Law, B., and Ardney, R. E. (1981). Preparation of 2-iodomorphine for use in RIA. J. Lab. Comp. Radio-pharm. 18, 1497–507.CrossRefGoogle Scholar
  32. Mould, G. P., Stout, G., Aherne, G. W., and Marks, V. (1978). Radioimmunoassay of amitriptyline and nortriptyline in body fluids. Ann. Clin. Biochem. 15, 221–52.CrossRefPubMedGoogle Scholar
  33. Mould, G. P., Clough, J., Morris, B. A., Stout, G., and Marks, V. (1981). A propranalol radioimmunoassay and its use in the study of its pharmacokinetics following low doses. Biopharm. Drug Disp. 2, 49–57.CrossRefGoogle Scholar
  34. Nordblom, G. D., Webb, R., Counsell, R. E., and England, B. G. (1981). A chemical approach to solving bridging phenomena in steroid radioimmunoassays. Steroids 38, 161–73.CrossRefPubMedGoogle Scholar
  35. Okabayashi, T., Mihara, S., Repke, D. B., and Moffatt, J. G. (1977). A radioimmunoassay for 1-β-D-arabinofuranosyluracil with reference to cross-reactivity of 1-β-D-arabinofuranosylcytosine with an antibody. Cancer Research 37, 3132–5.PubMedGoogle Scholar
  36. Oliver, G. C., Parker, B. H., Brasfield, D. L., and Parker, C. W. (1968). The measurement of digitoxin in human serum by radioimmunoassay. J. Clin. Invest. 47, 1035–42.PubMedCentralCrossRefPubMedGoogle Scholar
  37. Piall, E. M., Aherne, G. W., and Marks, V. (1982). Evaluation of a commercially available radioimmunoassay kit for the measurement of doxorubin (adramycin) in plasma. Clin. Chem. 28, 119–21.PubMedGoogle Scholar
  38. Ratcliffe, J. G., (1974). Separation techniques in saturation analysis. Br. Med. Bull. 30, 32–7.PubMedGoogle Scholar
  39. Robinson, J. D., Morris, B. A., Piall, E. M., Aherne, G. W., and Marks, V. (1975). In Pasternak, C. A. (ed.), Radioimmunoassay in Clinical Biochemistry, Heyden, London, 101–13.Google Scholar
  40. Robinson, J. D., Risby, D., Riley, G., and Aherne, G. W. (1978). A radioimmunoassay for the determination of combined amitriptyline and nortriptyline concentrations in microlitre samples of plasma. J. Pharmacol. Exp. Ther. 205, 499–502.PubMedGoogle Scholar
  41. Salacinsky, P., Hope, J., and McLean, C. (1979). A new simple method which allows theoretical incorporation of radioiodine into proteins and peptides without damage. J. Endoc. 81, 131.CrossRefGoogle Scholar
  42. Sizaret, P., Malaveille, C., Montesano, R., and Frayssinet, C. (1982). Detection of aflotoxins and related metabolites by radioimmunoassay. J. Natl. Cancer Inst. 69, 1375–81.PubMedGoogle Scholar
  43. Slevin, M. L., Piall, E. M., Aherne, G. W., Johnston, A., Sweatman, M. C., and Lister, T. A. (1981). The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukaemia. Br. J. Clin. Pharmac. 12, 507–10.CrossRefGoogle Scholar
  44. Smith, T. W., Butler, V. P., Haber, E., Fozzard, H., Marcus, F., Bremner, F., Schulman, I. and Phillips, A. (1982). Treatment of life-threatening digitalis intoxication with digoxin specific fab antibody fragments. New Engl. J. Med. 307, 1357–62.CrossRefPubMedGoogle Scholar
  45. Smith, J., Pearson, S., and Marks, V. (1982). Plasma caffeine concentrations in outpatients. Lancet ii, 985–6.CrossRefGoogle Scholar
  46. Smith, R. N. (1983). Radioimmunoassay in forensic science. Analyt. Proc. 20, 417–19.Google Scholar
  47. Soini, E., and Hemmila, I. (1979). Fluoroimmunoassay: Present status and key problems. Clin. Chem. 25, 353–61.PubMedGoogle Scholar
  48. Stoller, R. G., Hande, K. R., Jacobs, S. A., and Chabner, B. A. (1977). Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. New. Engl. J. Medicine 297, 630–4.CrossRefGoogle Scholar
  49. Teale, J. D., Clough, J. M., and Marks, V. (1977a). Radioimmunoassay of vinblastine and vincristine. Br. J. Clin. Pharmacol. 4, 160–72.CrossRefGoogle Scholar
  50. Teale, J. D., Clough, J. H., and Marks, V. (1977b). Radioimmunoassay of bleomycin in plasma and urine. Br. J. Cancer 33, 822–7.CrossRefGoogle Scholar
  51. Teale, J. D., Clough, J. M., King, L. J., Marks, V., Williams, P. L., and Moffat, A. C. (1977c). The incidence of cannabinoids in fatally injured drivers; an investigation by radioimmunoassay and high pressure liquid chromatography. J. Forens. Sci. Soc. 177–83.Google Scholar
  52. Thorell, J. I., and Johansson, B. G. (1971). Enzymatic iodination of polypeptides with 125I to high specific activity. Biochim. Biophys. Acta 251, 363–9.CrossRefPubMedGoogle Scholar
  53. Tigelaar, R. E., Rapport, R. L., Inman, J. K., and Kupferberg, H. J. (1973). A radioimmunoassay for diphenylhydantoin. Clin. Chim. Acta 43, 231–41.CrossRefPubMedGoogle Scholar
  54. Vellejo, R. P., Bogus, E. R., and Mumma, R. O. (1982). Effects of hapten structure and bridging groups on antisera specificity in parathion immunoassay development. J. Agric. Food Chem. 30, 572–80.CrossRefGoogle Scholar
  55. Vining, R. F., Compton, P., and McGinley, R. (1981). Steroid radioimmunoassay — effect of shortened incubation time on specificity. Clin. Chem. 27, 910–13.PubMedGoogle Scholar
  56. Voller, A., Bartlett, A., and Bidwell, D. E. (1978). Enzymeimmunoassays with special reference to ELISA techniques. J. Clin. Pathol. 31, 507–20.PubMedCentralCrossRefPubMedGoogle Scholar
  57. Williams, P. L., Moffat, A. C., and King, L. J. (1978). Combined high-pressure liquid chromatography and radioimmunoassay method for the quantitation of delta-9-tetrahydrocannabinol and some of its metabolites in human plasma. J. Chromatogr. 155, 273–83.CrossRefPubMedGoogle Scholar
  58. Yalow, R. S., and Berson, S. A. (1960). Immunoassay of endogenous plasma insulin in man. J. Clin. Invest. 39, 1157–75.PubMedCentralCrossRefPubMedGoogle Scholar
  59. Yalow, R. S., and Berson, S. A. (1970). In vitro Procedures with Radioisotopes in Clinical Medicine and Research. International Atomic Energy Agency, Vienna, 455–79.Google Scholar

Copyright information

© The contributors 1986

Authors and Affiliations

  • G. W. Aherne

There are no affiliations available

Personalised recommendations